Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients
Status:
Completed
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
This is a randomized controlled pilot study designed to evaluate whether the beta-adrenergic
antagonist propranolol is effective in decreasing gene expression of stress-mediated
beta-adrenergic pathways among a cohort of individuals receiving an autologous hematopoietic
stem cell transplant (HCT) for multiple myeloma.